1. Supportive Slides
Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item
Score range
Memory and new learning
0 - 35
Word recall (mean number of words not recalled)
0 - 10
Orientation (one point for each incorrect response)
0 - 8
Word recognition (mean number of incorrect responses)
0 - 12
Remembering test instructions
0 - 5
Language
0 - 25
Commands
Spoken language ability
Naming objects/fingers
Word-finding difficulty
Comprehension
Praxis
Constructional praxis
Ideational praxis
Total
0 - 70
Increasing scores indicate worsening cognitive function. Rosen WG, et al. Am J Psychiatry. 1984;141:

2. LS mean difference (95% CI).
Supportive Slides
Treatment Difference at Wk 24 on ADAS-cog by Country Core Study—ITT+RDO Population
Austria (N = 9)
Belgium (N = 21)
Canada (N = 41)
Germany (N = 63)
Spain (N = 59)
France (N = 63)
Great Britain (N = 48)
Italy (N = 118)
Netherlands (N = 18)
–39.67
46.92
Norway (N = 7)
–29.92
Portugal (N = 9)
Turkey (N = 45)
–20
–10 10 20
Favor placebo
Favor Exelon
LS mean difference (95% CI).

3. Supportive Slides
Duration of Nausea and Vomiting and Number of Events per Patient Core Study
Nausea
n (%)
Vomiting n (%)
Duration
Events, N = 137
Events, N = 77
1 - 7 days
55 (40.1)
47 (61.0)
days
16 (11.7)
7 (9.1)
days
13 (9.5)
8 (10.4)
days
11 (8.0)
5 (6.5)
> 28 days
22 (16.1)
4 (5.2)
Continuing†
20 (14.6)
6 (7.8)
Number of events/patient
Patients, N = 105
Patients, N = 60 1
81 (77.1)
49 (81.7) 2
19 (18.1)
8 (13.3) 3
2 (1.9)
1 (1.7)
> 3
3 (2.9)
2 (3.3)
† Events with no end dates recorded, which may or may not have resolved by last study visit.

4. Duration of Tremor and Number of These Events per Patient Core Study
Supportive Slides
Duration of Tremor and Number of These Events per Patient Core Study
Tremor
n (%)
Duration
Total events = 40
1 - 7 days
11 (27.5)
days
3 (7.5)
days
1 (2.5)
days
> 28 days
4 (10.0)
Continuing†
18 (45.0)
Number of events/patient
Total patients = 37 1 34 2 3
> 3
1 episode: 34 patients; 2 episodes: 3 patients.
† Events with no end dates recorded, which may or may not have resolved by last study visit.

5. AE of Tremor Over Time Core and Extension Studies
Supportive Slides
AE of Tremor Over Time Core and Extension Studies
Core
Extension
Exelon n/N (%)
Placebo n/N (%)
Exe-Exelon n/N (%)
Plc-Exelon n/N (%)
Titration period, wk
0 - 4
7/362 (1.9)
3/179 (1.7)
1/123 (0.8)
> 4 - 8
9/343 (2.6)
>
3/207 (1.4)
6/119 (5.0)
>
15/324 (4.6)
1/165 (0.6)
>
2/202 (1.0)
6/115 (5.2)
>
6/301 (2.0)
2/162 (1.2)
>
2/195 (1.0)
2/107 (1.9)
Maintenance period, wk
>
2/281 (0.7)
1/158 (0.6)
>
1/191 (0.5)
1/102 (1.0)
>
1/271 (0.4)
Patients are counted more than once if event continues through multiple periods.

6. Change on ADAS-cog Sub-items at Wk 24 Core Study—OC Population
Supportive Slides
Change on ADAS-cog Sub-items at Wk 24 Core Study—OC Population
Mean ± SD
Exelon (N = 290)
Placebo (N = 159)
ADAS-cog sub-item N
Change at Wk 24
p value†
Item 1: word recall
255
0.5 ± 1.3
139
0.1 ± 1.3
0.014*
Item 2: commands
258
0.3 ± 1.2
141
0.0 ± 1.3
0.023*
Item 3: constructional praxis
249
0.2 ± 1.0
135
–0.1 ± 1.1
0.095
Item 4: naming objects/fingers
0.1 ± 0.8
142
–0.1 ± 0.9
0.037*
Item 5: ideational praxis
245
0.4 ± 1.5
134
–0.1 ± 1.3
< 0.001*
Item 6: orientation
259
0.4 ± 1.8
143
–0.1 ± 1.7
0.060
Item 7: word recognition
0.5 ± 3.3
137
–0.2 ± 3.6
0.106
Item 8: remembering test instructions
256
0.2 ± 1.3
–0.1 ± 1.2
0.013*
Item 9: spoken language ability
0.1 ± 1.2
–0.3 ± 1.0
0.032*
Item 10: word finding difficulty
0.1 ± 1.0
0.0 ± 1.0
0.421
Item 11: comprehension
–0.2 ± 1.0
0.012*
*p < 0.05
† p value based on van Elteren test blocking for country.

7. Major Protocol Violations Core Study
Supportive Slides
Major Protocol Violations Core Study
Exelon
Placebo
Total
Protocol violation
N = 362 n (%)
N = 179 n (%)
N = 541 n (%)
≥ 1 protocol violation
82 (22.7)
33 (18.4)
115 (21.3)
MMSE score < 10 or > 24
6 (1.7)
3 (1.7)
9 (1.7)
Date diagnosis PD > date of first symptoms of PDD –2 yr
14 (3.9)
17 (3.1)
Increased dose or newly introduced psychotropic/ dopaminergic medication
39 (10.8)
18 (10.1)
57 (10.5)

8. Supportive Slides
Dopaminergic Agents— Dose Increase After Start of Study Drug Core Study
Exelon N = 362 n (%)
Placebo N = 179 n (%)
Dopa and dopa derivatives
20 (5.5)
8 (4.5)
Dopamine agonists
3 (0.8)
1 (0.6)
Other dopaminergic agents
2 (0.6)
Doses were required to remain unchanged unless clinically indicated.